- Business Wire•3 hours ago
FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted unanimously that the benefit-risk of rituximab/hyaluronidase for subcutaneous injection was favorable for the treatment of certain blood cancers, which include: previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma , relapsed ...
- Reuters•9 hours ago
The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).
- Business Wire•18 hours ago
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration approved OCREVUS™ as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.
RO.SW : Summary for ROCHE I - Yahoo Finance
Roche Holding AG (RO.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||253.50 - 255.50|
|52 Week Range||221.80 - 265.50|
|PE Ratio (TTM)||22.88|
|Dividend & Yield||8.22 (3.24%)|
|1y Target Est||N/A|